Breaking News Instant updates and real-time market news.

PIRS

Pieris Pharmaceuticals

$5.17

-0.14 (-2.64%)

, SNY

Sanofi

$41.96

-0.54 (-1.27%)

13:57
08/09/18
08/09
13:57
08/09/18
13:57

Sanofi, Roche discontinue collaborations with Pieris Pharmaceuticals

Pieris Pharmaceuticals (PIRS) disclosed earlier today in its earings release that it recently received notification of Roche's (RHHBY) intent to discontinue the companies' research collaboration and license agreement, effective August 21. The Roche collaboration, signed in 2015, pursued the discovery of Anticalin proteins specific for an exploratory immuno-oncology target selected by Roche. Pieris received an upfront payment of approximately $6.4M for the collaboration. Anticalin proteins generated under the collaboration will be wholly owned by the company. Pieris is "currently reviewing the data generated under this collaboration and will consider its strategic options thereafter," it added. In addition, Pieris said it recently received notification of Sanofi's (SNY) intent to return to Pieris all rights to the tetraspecific Anticalin program targeting P. aeruginosa, effective August 23. The program originated from a 2010 collaboration from which Pieris received an upfront payment of EUR 3.5M and three milestone payments totaling EUR 1.2M. Sanofi will transfer all related materials, data, and reports to Pieris, who will gain full control over the program. Pieris intends to "review this data package and consider its strategic options thereafter." The company added, "We remain on track to update investors with data from all three programs before year end. Our lead IO program, PRS-343, continues to advance apace in a dose-escalation study, and we expect to initiate a trial in combination with atezolizumab later this year. For PRS-060, our inhaled IL-4 receptor alpha antagonist program, we successfully completed the single-ascending dose inhalation phase in healthy volunteers and recently initiated a multiple-ascending dose study in subjects with mild asthma to test for early proof of concept via biomarkers."

PIRS

Pieris Pharmaceuticals

$5.17

-0.14 (-2.64%)

SNY

Sanofi

$41.96

-0.54 (-1.27%)

RHHBY

Roche

$0.00

(0.00%)

  • 09

    Aug

  • 09

    Aug

  • 14

    Aug

  • 25

    Aug

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

PIRS Pieris Pharmaceuticals
$5.17

-0.14 (-2.64%)

05/04/18
05/04/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Pieris Pharmaceuticals (PIRS) initiated with an Outperform at Cowen. 2. Extraction Oil & Gas (XOG) and ConvergeOne (CVON) were initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/04/18
COWN
05/04/18
INITIATION
COWN
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Pieris Pharmaceuticals with an Outperform rating ahead of the company's release of data for its two lead candidates. He believes the company's Anticalin technology represents a genuinely innovative platform for developing a novel class of drugs that address significant unmet needs across a range of disease areas.
03/19/18
03/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pieris Pharmaceuticals (PIRS) initiated with an Outperform at Evercore ISI and a Buy at Jefferies. 2. ConvergeOne (CVON) initiated with an Outperform at William Blair. 3. II-VI (IIVI) initiated with a Buy at Deutsche Bank. 4. Fitbit (FIT) initiated with a Buy at Craig-Hallum. 5. Fastenal (FAST) initiated with a Sell at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/18
EVER
03/19/18
INITIATION
Target $13
EVER
Outperform
Pieris Pharmaceuticals initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated Pieris Pharmaceuticals with an Outperform and $13 price target.
SNY Sanofi
$41.96

-0.54 (-1.27%)

08/09/18
WEDB
08/09/18
NO CHANGE
Target $77
WEDB
Outperform
MyoKardia price target raised to $77 from $64 at Wedbush
Wedbush analyst David Nierengarten raised his price target for MyoKardia (MYOK) to $77 from $64 as he now begins to value royalties on potential sales of mavacamten and MYK-491 in Europe based on increasing confidence that Sanofi (SNY) will elect to commercialize there. The analyst is also positive on MyoKardia ahead of the Phase 1b MYK-491 readout in dilated cardiomyopathy later this year, where a favorable safety profile and demonstration of clinical proof of mechanism could add at least $5/share to current levels. He reiterates an Outperform rating on MyoKardia shares.
08/01/18
EXAN
08/01/18
UPGRADE
EXAN
Outperform
Sanofi upgraded to Outperform from Neutral at Exane BNP Paribas
07/31/18
DBAB
07/31/18
NO CHANGE
DBAB
Sanofi added to catalyst call buy list at Deutsche Bank
07/19/18
BMOC
07/19/18
NO CHANGE
Target $80
BMOC
Market Perform
Eli Lilly to have a 'good Q2' on beats from launch franchises, says BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $80 from $78 ahead of its Q2 earnings, saying the company will have a "good" quarter on "beats from its launch franchises Trulicity, Jardiance, and Basaglar". The analyst also keeps his Market Perform rating, adding that while the the pipeline potential of its Galcanezumab and Tanezumab drugs is promising, he believes investors are underappreciating the headwinds around its diabetes program. He see higher risks of an increased biosimilar erosion for Humalog from Sanofi's (SNY) Admelog, and Trulicity competitive pressure from Novo's (NVO) Ozempic in 2019.
RHHBY Roche
$0.00

(0.00%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

10:05
12/13/18
12/13
10:05
12/13/18
10:05
General news
Treasury Option Action: put positioning in the belly »

Treasury Option Action:…

10:05
12/13/18
12/13
10:05
12/13/18
10:05
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

ROKU

Roku

$35.30

0.1301 (0.37%)

10:05
12/13/18
12/13
10:05
12/13/18
10:05
Conference/Events
Roku management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 18

    Dec

  • 19

    Dec

CTIC

CTI BioPharma

$1.49

(0.00%)

10:04
12/13/18
12/13
10:04
12/13/18
10:04
Hot Stocks
CTI BioPharma to cut approx. 50% of total workforce in restructuring »

CTI BioPharma announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,075.83

12.27 (1.15%)

, GOOGL

Alphabet Class A

$1,085.00

11.34 (1.06%)

10:04
12/13/18
12/13
10:04
12/13/18
10:04
Periodicals
Google employees instructed to treat TVCs differently, The Guardian reports »

Google employees are…

GOOG

Alphabet

$1,075.83

12.27 (1.15%)

GOOGL

Alphabet Class A

$1,085.00

11.34 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

TSLA

Tesla

$367.70

0.94 (0.26%)

10:04
12/13/18
12/13
10:04
12/13/18
10:04
On The Fly
Analyst sees narrative around Tesla changing as Wired reports on 'rage firings' »

Shares of Tesla (TSLA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MGLN

Magellan Health

$61.38

2.75 (4.69%)

10:03
12/13/18
12/13
10:03
12/13/18
10:03
Hot Stocks
Magellan rallies after activist Starboard discloses nearly 10% stake »

Jeff Smith's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTI

TechnipFMC

$20.67

-0.57 (-2.68%)

10:01
12/13/18
12/13
10:01
12/13/18
10:01
Upgrade
TechnipFMC rating change  »

BMO Capital says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PYPL

PayPal

$88.01

1.51 (1.75%)

10:01
12/13/18
12/13
10:01
12/13/18
10:01
Conference/Events
PayPal management to meet with Wedbush »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 13

    Dec

  • 13

    Dec

  • 18

    Dec

OXM

Oxford Industries

$67.67

-7.21 (-9.63%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Oxford Industries falls -9.0% »

Oxford Industries is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$58.45

-6.2 (-9.59%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -9.8% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$14.56

-5.6 (-27.78%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Tailored Brands falls -27.5% »

Tailored Brands is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.99

0.73 (13.88%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Qudian rises 13.9% »

Qudian is up 13.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAC

Macerich

$48.91

1.78 (3.78%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Options
Call buyers in Macerich as shares gain 3% »

Call buyers in Macerich…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$35.52

3.385 (10.53%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Ciena rises 11.5% »

Ciena is up 11.5%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

VNCE

Vince Holding

$9.92

(0.00%)

10:00
12/13/18
12/13
10:00
12/13/18
10:00
Hot Stocks
Vince Holding rises 16.1% »

Vince Holding is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

XPO

XPO Logistics

$59.58

-0.67 (-1.11%)

09:55
12/13/18
12/13
09:55
12/13/18
09:55
Options
XPO Logistics put volume heavy and directionally bearish »

Bearish flow noted in XPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.37

0.65 (9.67%)

, AFL

Aflac

$45.33

2.44 (5.69%)

09:55
12/13/18
12/13
09:55
12/13/18
09:55
Options
Early notable gainers among liquid option names on December 13th »

Notable gainers among…

GE

General Electric

$7.37

0.65 (9.67%)

AFL

Aflac

$45.33

2.44 (5.69%)

MAC

Macerich

$48.39

1.26 (2.67%)

KMB

Kimberly-Clark

$115.99

2.12 (1.86%)

FSLR

First Solar

$44.40

0.8 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

HIIQ

Health Insurance Innovations

$30.02

-0.045 (-0.15%)

09:55
12/13/18
12/13
09:55
12/13/18
09:55
Conference/Events
Health Insurance Innovations to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

XPO

XPO Logistics

$59.87

-0.385 (-0.64%)

09:53
12/13/18
12/13
09:53
12/13/18
09:53
Hot Stocks
Spruce Point calls XPO financials 'dubious,' sees up to 100% downside risk »

Short seller Spruce Point…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:50
12/13/18
12/13
09:50
12/13/18
09:50
General news
Treasury 30-year auction outlook: »

Treasury 30-year auction…

ARMK

Aramark

$32.76

0.65 (2.02%)

09:50
12/13/18
12/13
09:50
12/13/18
09:50
Recommendations
Aramark analyst commentary  »

Aramark price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$58.95

-1.3 (-2.16%)

09:48
12/13/18
12/13
09:48
12/13/18
09:48
Periodicals
Spruce Point names XPO Logistics a 'Strong Sell,' sees '100% long-term downside' »

Spruce Point Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNT

Unit Corp.

$18.33

-0.755 (-3.96%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
Unit Corp. falls -5.2% »

Unit Corp. is down -5.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$57.49

-7.16 (-11.08%)

09:47
12/13/18
12/13
09:47
12/13/18
09:47
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -11.3% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.